Current Treatment Options in Neurology

, Volume 15, Issue 1, pp 13–27 | Cite as

Familial and Sporadic Hemiplegic Migraine: Diagnosis and Treatment

  • Nadine Pelzer
  • Anine H. Stam
  • Joost Haan
  • Michel D. Ferrari
  • Gisela M. Terwindt

Opinion statement

Hemiplegic migraine (HM) is a rare subtype of migraine with aura, characterized by transient hemiparesis during attacks. Diagnosis is based on the International Classification of Headache Disorders criteria (ICHD-II). Two types of HM are recognized: familial (FHM) and sporadic hemiplegic migraine (SHM). HM is genetically heterogeneous. Three genes have been identified (CACNA1A, ATP1A2, and SCN1A) but more, so far unknown genes, are involved. Clinically, attacks of the 3 subtypes cannot be distinguished. The diagnosis can be confirmed but not ruled out by genetic testing, because in some HM patients other, not yet identified, genes are involved. The presence of additional symptoms (such as chronic ataxia or epilepsy) may increase the likelihood of identifying a mutation. Additional diagnostics like imaging, CSF analysis, or an EEG are mainly performed to exclude other causes of focal neurological symptoms associated with headache. Conventional cerebral angiography is contraindicated in HM because this may provoke an attack. Because HM is a rare condition, no clinical treatment trials are available in this specific subgroup of migraine patients. Thus, the treatment of HM is based on empirical data, personal experience of the treating neurologist, and involves a trial-and-error strategy. Acetaminophen and NSAIDs often are the first choice in acute treatment. Although controversial in HM, triptans can be prescribed when headaches are not relieved sufficiently with common analgesics. An effective treatment for the severe and often prolonged aura symptoms is more warranted, but currently no such acute treatment is available. Prophylactic treatment can be considered when attack frequency exceeds 2 attacks per month, or when severe attacks pose a great burden that requires reduction of severity and frequency. In no strictly preferred order, flunarizine, sodium valproate, lamotrigine, verapamil, and acetazolamide can be tried. While less evidence is available for prophylactic treatment with topiramate, candesartan, and pizotifen, these drugs can also be considered. The use of propranolol in HM is more controversial, but evidence of adverse effects is insufficient to contraindicate beta-blockers.


Migraine Familial hemiplegic migraine Sporadic hemiplegic migraine Cortical spreading depression Channelopathies CACNA1A gene ATP1A2 gene SCN1A gene Imaging CSF analysis Electroencephalography Prophylactic treatment Acute treatment Antiepileptic drugs Calcium antagonists Triptans Ergot alkaloids CGRP receptor antagonists Beta-blockers 



This work was supported by grants of the Netherlands Organization for Scientific Research (NWO) (VICI 918.56.602, M.D.F.; 907-00-217, G.M.T.; 920-03-473, A.H.S.; VIDI 91711319, G.M.T.)


Dr. Pelzer received support for conference visits from Menarini and Allergan UK. Dr. Ferrari received grant and consultancy or industry support from Almirall, Coherex, Colucid, Eisai, GlaxoSmithKline, Linde, MAP, Medtronic, Menarini, Merck & Co., Minster, Pfizer, Allergan, and St. Jude and independent support from NWO, NIH, European Community FP6, Biomed EC, and the Dutch Heart Foundation. Dr. Terwindt received grant and consultancy/industry support from Merck & Co., Janssen-Cilag, Allergan, and Menarini, and independent support from NWO. Dr. Stam and Dr. Haan reported no potential conflicts of interest relevant to this article.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as • Of importance

  1. 1.
    Thomsen LL, Kirchmann EM, Faerch RS, et al. An epidemiological survey of hemiplegic migraine. Cephalalgia. 2002;22:361–75.CrossRefGoogle Scholar
  2. 2.
    The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.Google Scholar
  3. 3.
    Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med. 2002;346:257–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117(Pt 1):199–210.PubMedCrossRefGoogle Scholar
  5. 5.
    Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol. 1981;9:344–52.PubMedCrossRefGoogle Scholar
  6. 6.
    Hadjikhani N, Sanchez Del Rio M, Wu O, et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA. 2001;98:4687–92.PubMedCrossRefGoogle Scholar
  7. 7.
    Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep. 2003;7:55–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993;14:129–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Schoonman GG, Van Der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation–a 3 T magnetic resonance angiography study. Brain. 2008;131:2192–200.PubMedCrossRefGoogle Scholar
  10. 10.
    Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011;69:635–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Stam AH, Haan J, van den Maagdenberg AMJM, et al. Migraine and genetic and acquired vasculopathies. Cephalalgia. 2009;29:1006–17.PubMedCrossRefGoogle Scholar
  12. 12.
    Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Thomsen LL, Olesen J, Russell MB. Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. Eur J Neurol. 2003;10:421–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Eriksen MK, Thomsen LL, Olesen J. Implications of clinical subtypes of migraine with aura. Headache. 2006;46:286–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Haan J, Terwindt GM, Ophoff RA, et al. Is familial hemiplegic migraine a hereditary form of basilar migraine? Cephalalgia. 1995;15:477–81.PubMedGoogle Scholar
  16. 16.•
    Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol. 2011;10:457–70. An excellent and extensive review article about many aspects of HM.PubMedCrossRefGoogle Scholar
  17. 17.
    Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;345:17–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Kors EE, Terwindt GM, Vermeulen FL, et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol. 2001;49:753–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Jurkat-Rott K, Freilinger T, Dreier JP, et al. Variability of familial hemiplegic migraine with novel ATP1A2 Na+/K + -ATPase variants. Neurology. 2004;62:1857–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543–52.PubMedCrossRefGoogle Scholar
  21. 21.
    de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AMJM. Molecular genetics of migraine. Hum Genet. 2009;126:115–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Kors EE, Haan J, Giffin NJ, et al. Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation: a description of 5 families with familial hemiplegic migraine. Arch Neurol. 2003;60:684–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Riant F, De Fusco M, Aridon P, et al. ATP1A2 mutations in 11 families with familial hemiplegic migraine. Hum Mutat. 2005;26:281.PubMedCrossRefGoogle Scholar
  24. 24.
    Lebas A, Guyant-Marechal L, Hannequin D, et al. Severe attacks of familial hemiplegic migraine, childhood epilepsy and ATP1A2 mutation. Cephalalgia. 2008;28:774–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Vanmolkot KR, Stroink H, Koenderink JB, et al. Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation. Ann Neurol. 2006;59:310–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Spadaro M, Ursu S, Lehmann-Horn F, et al. A G301R Na+/K + -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs. Neurogenetics. 2004;5:177–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;366:371–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Riant F, Ducros A, Ploton C, et al. De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine. Neurology. 2010;75:967–72.PubMedCrossRefGoogle Scholar
  29. 29.
    de Vries B, Freilinger T, Vanmolkot KR, et al. Systematic analysis of three FHM genes in 39 sporadic patients with hemiplegic migraine. Neurology. 2007;69:2170–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Thomsen LL, Kirchmann M, Bjornsson A, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain. 2007;130:346–56.PubMedCrossRefGoogle Scholar
  31. 31.
    Stuart S, Roy B, Davies G, et al. Detection of a novel mutation in the CACNA1A gene. Twin Res Hum Genet. 2012;15:120–5.PubMedCrossRefGoogle Scholar
  32. 32.
    Thomsen LL, Oestergaard E, Bjornsson A, et al. Screen for CACNA1A and ATP1A2 mutations in sporadic hemiplegic migraine patients. Cephalalgia. 2008;28:914–21.PubMedCrossRefGoogle Scholar
  33. 33.
    Terwindt G, Kors E, Haan J, et al. Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch Neurol. 2002;59:1016–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Vahedi K, Denier C, Ducros A, et al. CACNA1A gene de novo mutation causing hemiplegic migraine, coma, and cerebellar atrophy. Neurology. 2000;55:1040–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Hayashi R, Tachikawa H, Watanabe R, et al. Familial hemiplegic migraine with irreversible brain damage. Intern Med. 1998;37:166–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Butteriss DJ, Ramesh V, Birchall D. Serial MRI in a case of familial hemiplegic migraine. Neuroradiology. 2003;45:300–3.PubMedGoogle Scholar
  37. 37.
    Spacey SD, Vanmolkot KR, Murphy C, et al. Familial hemiplegic migraine presenting as recurrent encephalopathy in a Native Indian family. Headache. 2005;45:1244–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Ohmura K, Suzuki Y, Saito Y, et al. Sporadic hemiplegic migraine presenting as acute encephalopathy. Brain Dev. 2012;34:691–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Bhatia R, Desai S, Tripathi M, et al. Sporadic hemiplegic migraine: report of a case with clinical and radiological features. J Headache Pain. 2008;9:385–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Jacob A, Mahavish K, Bowden A, et al. Imaging abnormalities in sporadic hemiplegic migraine on conventional MRI, diffusion and perfusion MRI and MRS. Cephalalgia. 2006;26:1004–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Dreier JP, Jurkat-Rott K, Petzold GC, et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology. 2005;64:2145–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Iizuka T, Sakai F, Suzuki K, et al. Implication of augmented vasogenic leakage in the mechanism of persistent aura in sporadic hemiplegic migraine. Cephalalgia. 2006;26:332–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Mjaset C, Russell MB. Intravenous nimodipine worsening prolonged attack of familial hemiplegic migraine. J Headache Pain. 2008;9:381–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Beauvais K, Cave-Riant F, De Barace C, et al. New CACNA1A gene mutation in a case of familial hemiplegic migraine with status epilepticus. Eur Neurol. 2004;52:58–61.PubMedCrossRefGoogle Scholar
  45. 45.
    Prodan CI, Holland NR, Lenaerts ME, Parke JT. Magnetic resonance angiogram evidence of vasospasm in familial hemiplegic migraine. J Child Neurol. 2002;17:470–2.PubMedCrossRefGoogle Scholar
  46. 46.
    Gonzalez-Alegre P, Tippin J. Prolonged cortical electrical depression and diffuse vasospasm without ischemia in a case of severe hemiplegic migraine during pregnancy. Headache. 2003;43:72–5.PubMedCrossRefGoogle Scholar
  47. 47.
    Pierelli F, Grieco GS, Pauri F, et al. A novel ATP1A2 mutation in a family with FHM type II. Cephalalgia. 2006;26:324–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Motta E, Rosciszewska D, Miller K. Hemiplegic migraine with CSF abnormalities. Headache. 1995;35:368–70.PubMedCrossRefGoogle Scholar
  49. 49.
    Gomez-Aranda F, Canadillas F, Marti-Masso JF, et al. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases. Brain. 1997;120(Pt 7):1105–13.PubMedCrossRefGoogle Scholar
  50. 50.
    Berg MJ, Williams LS. The transient syndrome of headache with neurologic deficits and CSF lymphocytosis. Neurology. 1995;45:1648–54.PubMedCrossRefGoogle Scholar
  51. 51.
    Yilmaz A, Kaleagasi H, Dogu O, et al. Abnormal MRI in a patient with ‘headache with neurological deficits and CSF lymphocytosis (HaNDL). Cephalalgia. 2010;30:615–9.PubMedGoogle Scholar
  52. 52.
    Raets I. Diffusion restriction in the splenium of the corpus callosum in a patient with the syndrome of transient headache with neurological deficits and CSF lymphocytosis (HaNDL): a challenge to the diagnostic criteria? Acta Neurol Belg. 2012;112:67–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Chapman KM, Szczygielski BI, Toth C, et al. Pseudomigraine with lymphocytic pleocytosis: a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A. Headache. 2003;43:892–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Heinzen EL, Swoboda KJ, Hitomi Y, et al. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet. 2012;44:1030–4.PubMedCrossRefGoogle Scholar
  55. 55.
    Hutchinson M, O’Riordan J, Javed M, et al. Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Ann Neurol. 1995;38:817–24.PubMedCrossRefGoogle Scholar
  56. 56.
    Montagna P, Gallassi R, Medori R, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology. 1988;38:751–4.PubMedCrossRefGoogle Scholar
  57. 57.
    Hansen JM, Hauge AW, Ashina M, Olesen J. Trigger factors for familial hemiplegic migraine. Cephalalgia. 2011;31:1274–81.PubMedCrossRefGoogle Scholar
  58. 58.
    Schoonman GG, Evers DJ, Ballieux BE, et al. Is stress a trigger factor for migraine? Psychoneuroendocrinology. 2007;32:532–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Ye Q, Yan LY, Xue LJ, et al. Flunarizine blocks voltage-gated Na(+) and Ca(2+) currents in cultured rat cortical neurons: a possible locus of action in the prevention of migraine. Neurosci Lett. 2011;487:394–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Tobita M, Hino M, Ichikawa N, et al. A case of hemiplegic migraine treated with flunarizine. Headache. 1987;27:487–8.PubMedCrossRefGoogle Scholar
  61. 61.
    De Cunto A, Bensa M, Tonelli A. A case of familial hemiplegic migraine associated with a novel ATP1A2 gene mutation. Pediatr Neurol. 2012;47:133–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Mohamed BP, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years’ experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol. 2012;54:274–7.CrossRefGoogle Scholar
  63. 63.
    Dobrev D, Milde AS, Andreas K, Ravens U. The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. Br J Pharmacol. 1999;127:576–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Yu W, Horowitz SH. Familial hemiplegic migraine and its abortive therapy with intravenous verapamil. Neurology. 2001;57:1732–3.PubMedCrossRefGoogle Scholar
  65. 65.
    Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology. 2003;60:120–1.PubMedCrossRefGoogle Scholar
  66. 66.
    Razavi M, Razavi B, Fattal D, et al. Hemiplegic migraine induced by exertion. Arch Neurol. 2000;57:1363–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997;17:93–100.PubMedCrossRefGoogle Scholar
  68. 68.
    Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.PubMedCrossRefGoogle Scholar
  69. 69.
    Rothrock JF. Successful treatment of persistent migraine aura with divalproex sodium. Neurology. 1997;48:261–2.PubMedCrossRefGoogle Scholar
  70. 70.
    Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol. 1996;307:113–6.PubMedCrossRefGoogle Scholar
  71. 71.
    Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17:109–12.PubMedCrossRefGoogle Scholar
  72. 72.
    Chen WT, Fuh JL, Lu SR, Wang SJ. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache. 2001;41:823–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura–a pilot study. Cephalalgia. 1999;19:58–63.PubMedCrossRefGoogle Scholar
  74. 74.
    D’Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia. 1999;19:64–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76:1730–2.PubMedCrossRefGoogle Scholar
  76. 76.
    Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache. 2004;44:1024–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Strupp M, Zwergal A, Brandt T. Episodic ataxia type 2. Neurotherapeutics. 2007;4:267–73.PubMedCrossRefGoogle Scholar
  78. 78.
    Battistini S, Stenirri S, Piatti M, et al. A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia. Neurology. 1999;53:38–43.PubMedCrossRefGoogle Scholar
  79. 79.
    Athwal BS, Lennox GG. Acetazolamide responsiveness in familial hemiplegic migraine. Ann Neurol. 1996;40:820–1.PubMedCrossRefGoogle Scholar
  80. 80.
    Koch HJ, Sykora A, Hausn P. Off-label use of acetazolamide in a patient with familial hemiplegic migraine and concomitant psychotic episodes. Psychiatr Prax. 2010;37:148–51.PubMedCrossRefGoogle Scholar
  81. 81.
    De Simone R, Marano E, Di Stasio E, et al. Acetazolamide efficacy and tolerability in migraine with aura: a pilot study. Headache. 2005;45:385–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Vahedi K, Taupin P, Djomby R, et al. Efficacy and tolerability of acetazolamide in migraine prophylaxis: a randomized placebo-controlled trial. J Neurol. 2002;249:206–11.PubMedCrossRefGoogle Scholar
  83. 83.
    Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22:491–512.PubMedCrossRefGoogle Scholar
  84. 84.
    Striano P, Zara F, Santorelli FM, Striano S. Topiramate-associated worsening symptoms in a patient with familial hemiplegic migraine. J Neurol Sci. 2008;272:194–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Bardwell A, Trott JA. Stroke in migraine as a consequence of propranolol. Headache. 1987;27:381–3.PubMedCrossRefGoogle Scholar
  86. 86.
    Olesen J, Hougard K, Hertz M. Isoproterenol and propranolol: ability to cross the blood-brain barrier and effects on cerebral circulation in man. Stroke. 1978;9:344–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Zifkin B, Andermann E, Andermann F, Kirkham T. An autosomal dominant syndrome of hemiplegic migraine, nystagmus, and tremor. Ann Neurol. 1980;8:329–32.PubMedCrossRefGoogle Scholar
  88. 88.
    Lai CW, Ziegler DK, Lansky LL, Torres F. Hemiplegic migraine in childhood: diagnostic and therapeutic aspects. J Pediatr. 1982;101:696–9.PubMedCrossRefGoogle Scholar
  89. 89.
    Hsu DA, Stafstrom CE, Rowley HA, et al. Hemiplegic migraine: hyperperfusion and abortive therapy with intravenous verapamil. Brain Dev. 2008;30:86–90.PubMedCrossRefGoogle Scholar
  90. 90.
    Omata T, Takanashi J, Wada T, et al. Genetic diagnosis and acetazolamide treatment of familial hemiplegic migraine. Brain Dev. 2011;33:332–4.PubMedCrossRefGoogle Scholar
  91. 91.
    Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(Pt 1):9–18.PubMedCrossRefGoogle Scholar
  92. 92.
    Maassen van den Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998;98:25–30.CrossRefGoogle Scholar
  93. 93.
    Klapper J, Mathew N, Nett R. Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache. 2001;41:981–84.PubMedCrossRefGoogle Scholar
  94. 94.
    Artto V, Nissila M, Wessman M, et al. Treatment of hemiplegic migraine with triptans. Eur J Neurol. 2007;14:1053–6.PubMedCrossRefGoogle Scholar
  95. 95.
    Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77:441–4.PubMedCrossRefGoogle Scholar
  96. 96.
    Kaube H, Herzog J, Kaufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000;55:139–41.PubMedCrossRefGoogle Scholar
  97. 97.
    Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73:970–7.PubMedCrossRefGoogle Scholar
  98. 98.
    Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–23.PubMedCrossRefGoogle Scholar
  99. 99.•
    Hoffmann J, Goadsby PJ. New agents for acute treatment of migraine: CGRP Receptor Antagonists, iNOS Inhibitors. Curr Treat Options Neurol. 2012;14:50–9. A clear and recent review article about future pharmacological treatment options in migraine.PubMedCrossRefGoogle Scholar
  100. 100.
    Jenkins B, Tepper SJ. Neurostimulation for primary headache disorders, part 1: pathophysiology and anatomy, history of neuromodulation in headache treatment, and review of peripheral neuromodulation in primary headaches. Headache. 2011;51:1254–66.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Nadine Pelzer
    • 1
  • Anine H. Stam
    • 1
  • Joost Haan
    • 1
    • 2
  • Michel D. Ferrari
    • 1
  • Gisela M. Terwindt
    • 1
  1. 1.Department of NeurologyLeiden University Medical CenterRC LeidenThe Netherlands
  2. 2.Department of NeurologyRijnland HospitalCC LeiderdorpThe Netherlands

Personalised recommendations